Latest News and Press Releases

– Approximately 82% of Annual Base Rent from Industrial Properties –– Acquires 23 Industrial Properties for $245.5 Million in 2025 and Subsequent to Year End –– Completes Sale of 12 Non-Core Assets...

– Increased or Maintained Dividend for Over 33 Consecutive Years – GREAT NECK, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- One Liberty Properties, Inc. (NYSE: OLP) today announced that its Board of...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of...

Ferrellgas Partners, L.P. reports second quarter fiscal year 2026 results

Itron has expanded its universal software suite to support two communication modules: the Itron Cellular 500G Module and the Itron Cellular 500W Module.

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study...

Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans...